Blog

GISTs with PDGFRA mutation show lower 18F-FDG uptake compared to other molecular subtypes

mdanderson.org

Jan 27, 2025, 08:54

GISTs with PDGFRA mutation show lower 18F-FDG uptake compared to other molecular subtypes

Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared an article by Maria Concetta Nigro on LinkedIn:

“GISTs with PDGFRA mutation show lower 18F-FDG uptake compared to other molecular subtypes, especially KIT exon 11–mutant GISTs JAMA Network Open.

Median SUVmax in D842V-mutant GISTs:

Median SUVmax in non-D842V-mutant GISTs: 3.6
• Median SUVmax in KIT exon 11-mutant GISTs: 10.1
• Clinical Relevance: Low FDG uptake in PDGFRA-mutant GISTs may limit the utility of FDG-PET in this subgroup but raises questions about its prognostic and predictive value.

Molecular Era Needs Molecular Imaging.”

18F-Fluorodeoxyglucose Uptake in ***PDGFRA*-Mutant Gastrointestinal Stromal Tumors.**

Authors: Maria Concetta Nigro, et al.

GISTs with PDGFRA mutation show lower 18F-FDG uptake compared to other molecular subtypes

cancer D842V Elvina Almuradova European Institute of Oncology fight against cancer Fluorodeoxyglucose Gastrointestinal Stromal Tumors GISTs Global fight against cancer JAMA Network Open molecular imaging OncoDaily Oncology PDGFRA mutation

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial

John Cena Announces He Overcame Skin Cancer Twice, Advocates for Sun Safety

William N. Hait to Receive 2025 AACR-Margaret Foti Award for Leadership in Cancer Research